Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osilodrostat Long-term Safety in Endogenous Cushing’s Syndrome
CTR20191077Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of osilodrostat in Cushing's syndrome, sponsored by Novartis. Started Jul 2019; status: completed.
02
Drugs
osilodrostat
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on CTR20191077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191077.